Biotechnology
Sitryx To Participate In Upcoming April Investor Conferences
Share
Oxford, UK and Boston, MA – March 26, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences:
Wells Fargo Spring Virtual Private Biopharma Symposium
Date: Wednesday, April 8, 2026
Format: Virtual
Needham & Company 25th Annual Healthcare Conference
Date: Monday, April 13 – Thursday, April 16, 2026
Format: Virtual
H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Date: Tuesday, April 14 – Wednesday, April 15, 2026
Format: Virtual
Piper Sandler Spring Biopharma Symposium
Date: Wednesday, April 15 – Thursday, April 16, 2026
Location: Boston, MA
Management will be in attendance to participate in one-on-one and group meetings during each event. Interested investors should contact their Wells Fargo, Needham & Company, H.C. Wainwright and Piper Sandler representatives, respectively, to schedule meetings.
Ends
For more information about Sitryx please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Evi Useh
+44 (0)20 3709 5700
Sitryx@icrhealthcare.com
About Sitryx
Sitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.
Established with seed funding from SV Health Investors, Sitryx has an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.
Sitryx is headquartered in Oxford, UK with additional presence in Boston, MA. For more information, please visit www.sitryx.com.
Frequently Asked Questions
What is Sitryx Therapeutics?
Sitryx Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases.
Which investor conferences will Sitryx management be attending?
Sitryx management will be participating in the Wells Fargo Spring Virtual Private Biopharma Symposium, Needham & Company 25th Annual Healthcare Conference, H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference, and Piper Sandler Spring Biopharma Symposium.
What is Sitryx's lead therapeutic candidate?
Sitryx's lead candidate is SYX-5219, a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.
First published on Fri, Mar 27, 2026
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending GlobeNewswire
Expanded Madcap Syndicate Intelligent Content Delivery Platform Brings Next-Level AI Enablement To Corporate Content
Instride And Beyond Banyan Partner To Strengthen Value Realization For Employer-Sponsored Education And Skilling Solutions
Nordlayer Launches Browser, Delivering User And Business-Friendly Advanced Security For Smbs
Optery Ranked No. 12 Fastest-Growing Private Company In 2026 Inc. Regionals: Pacific List
QCI Advances Dispatch Capabilities With Modernized, Fully Integrated Platform
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion